First Jury Verdict For Private Plaintiffs In Pay-For-Delay Litigation Results In $885 Million Award

Why It Matters

The verdict signals that courts are willing to hold pharma companies accountable for reverse‑payment agreements, potentially reshaping generic‑drug settlement strategies and lowering drug costs for consumers and payors.

Key Takeaways

• Jury awards $885 million in first pay‑for‑delay verdict
• Generic Amitiza entry delayed until 2021 under settlement
• Damages may treble, pushing exposure to billions
• Case applies Actavis rule of reason to reverse payments

Pulse Analysis

The $885 million verdict in the Amitiza pay‑for‑delay case represents a watershed moment for antitrust enforcement in the pharmaceutical sector. Historically, manufacturers have used reverse‑payment settlements to postpone generic competition, arguing patent protection as a shield. By applying the Actavis rule of reason, the jury rejected that defense, finding the royalty and launch delay unreasonable and harmful to market competition. This decision underscores a growing judicial appetite to scrutinize settlement structures that inflate drug prices, especially when they exploit the 180‑day exclusivity granted to first generic applicants.

Amitiza, approved in 2006 for chronic constipation and related conditions, commanded a premium price that could have fallen dramatically with earlier generic entry. The settlement forced Par Pharmaceutical to postpone its launch until 2021 and accept a 50 % royalty—well below the industry norm of 90 %—effectively paying the brand‑name holder to keep competition at bay. Plaintiffs argued that, absent the agreement, a generic would have reached the market by 2016, delivering substantial savings to patients, insurers, and retailers. The jury’s damage allocation—$474 million to direct purchasers, $63 million to insurers, and $346 million to retailers—highlights the broad financial impact of delayed competition across the supply chain.

The broader implications for the industry are profound. Companies may now face heightened risk when negotiating reverse‑payment settlements, prompting a shift toward more transparent, royalty‑based licensing that aligns with market standards. Lawmakers and regulators could leverage this precedent to tighten guidance on anticompetitive agreements, potentially encouraging earlier generic launches and lower drug prices. As the defendant prepares an appeal, the case will be closely watched for its influence on future antitrust litigation and settlement practices in the pharmaceutical market.